MARKET

ENTA

ENTA

Enanta Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.13
+0.76
+1.60%
After Hours: 47.95 -0.18 -0.38% 16:11 08/12 EDT
OPEN
47.53
PREV CLOSE
47.37
HIGH
48.52
LOW
47.10
VOLUME
149.19K
TURNOVER
--
52 WEEK HIGH
74.51
52 WEEK LOW
38.40
MARKET CAP
962.80M
P/E (TTM)
654.83
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ENTA stock price target is 66.83 with a high estimate of 119.00 and a low estimate of 45.00.

EPS

ENTA News

More
Were Hedge Funds Right About Ditching Enanta Pharmaceuticals Inc (ENTA)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional invest
Insider Monkey · 5d ago
Enanta Pharmaceuticals Inc (ENTA) Q3 2020 Earnings Call Transcript
Image source: The Motley Fool. Enanta Pharmaceuticals Inc (NASDAQ: ENTA)Q3 2020 Earnings CallAug 4, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to Enanta Pharmace
Motley Fool · 08/05 05:31
Enanta Pharma EPS beats by $0.26, misses on revenue
Enanta Pharma (NASDAQ:ENTA): Q3 GAAP EPS of -$0.71 beats by $0.26. Revenue of $18.65M (-58.0% Y/Y) misses by $6.82M. Press Release
seekingalpha · 08/05 01:05
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 2.74% and -37.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 22:35
Enanta Pharmaceuticals Q3 EPS $(0.71) Beats $(0.77) Estimate, Sales $18.65M Miss $27.89M Estimate
Enanta Pharmaceuticals (NASDAQ:ENTA) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.79 percent. This is a 315.15 percent decrease over earnings of $0.33 per share
Benzinga · 08/04 20:03
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m.
Business Wire · 08/04 20:01
Enanta Pharma Q3 2020 Earnings Preview
Enanta Pharma (NASDAQ:ENTA) is scheduled to announce Q3 earnings results on Tuesday, August 4th, after market close. The consensus EPS Estimate is -$0.96 (
seekingalpha · 08/04 02:35
Enanta Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference 2020
Enanta Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference 2020
Business Wire · 08/03 11:02

Industry

Biotechnology & Medical Research
+0.70%
Pharmaceuticals & Medical Research
+1.61%

Hot Stocks

Symbol
Price
%Change

About ENTA

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
More

Webull offers kinds of Enanta Pharmaceuticals Inc stock information, including NASDAQ:ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.